InveniAI Appoints Industry Leader Dr. Salvatore Alesci as

InveniAI Appoints Industry Leader Dr. Salvatore Alesci as

News Highlights

  • Pipeline to include new chemical entities as well as re-innovated drugs, all targeting dysregulation of the gut-brain axis and inflammasome pathways for chronic inflammatory diseases
  • Dr. Alesci’s proven track record in optimizing early-stage drug development of multiple programs in various therapeutic areas will be key as the company leverages its AI-platform to advance and diversify its portfolio

GUILFORD, Conn., May 11, 2021 (News) — InveniAI® LLC, a global leader in pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across drug discovery and development, announced today the appointment of Salvatore (Salvo) Alesci, M.D., Ph.D., as its Chief Scientific Officer. Dr. Alesci, a physician-scientist, R&D strategist, and science policy influencer with expertise in translational medicine, will be responsible for advancing programs from IND-enabling to human proof-of-concept studies and working with the leadership team on scientific and business strategies. The company’s AI-driven pipeline currently has three programs prioritized for development that address the intersection of the Gut-Brain Axis (GBA) and chronic inflammatory diseases of the gastrointestinal (GI) tract.

For every ten adults in the world, four suffer from functional GI disorders of varying severity. Two-thirds of these people will have chronic, fluctuating symptoms1. While the pathophysiology of functional GI disorders is multifaceted, it is known that bidirectional dysregulation of the GBA, including altered mucosal immune function, visceral hypersensitivity, and abnormal gastrointestinal motility plays a key role in these disorders1. InveniAI harnesses its AI platform AlphaMeld® to deconvolute the complex network of GBA pathways and generate hypotheses across the entire spectrum of pathophysiological processes involved in inflammatory gut diseases, from induction to early mucosal damage and fibrosis. AlphaMeld® has already helped identify drug candidates with demonstrated safety. Initial programs will target the potential treatment of irritable bowel syndrome (IBS), inflammatory bowel disease (IBD), and rare gastrointestinal disorders, with the first NDA filing projected for 2025.

Dr. Krishnan Nandabalan, Ph.D., Founder, President, and CEO, InveniAI, said, “I’m delighted to have Salvo join the InveniAI team during this next phase of growth. I’m looking forward to working closely with him as we rapidly advance our portfolio of therapies for chronic inflammatory GI-diseases, with plans to scale these efforts in the near term. As a highly accomplished and proven leader, Salvo brings with him a breadth of knowledge in running drug discovery programs at the pre-clinical and clinical level and is a proponent of innovative approaches to biopharmaceutical discovery and development.”

“InveniAI’s vision of leveraging AI to deconvolute and de-risk drug discovery and development is particularly exciting to me, as I strive to progress and bring novel medicines to patients in need,” said Salvatore Alesci, M.D., Ph.D. CSO, InveniAI “I’m thrilled to join an outstanding team in deploying cutting-edge AI-technology to decode the GBA and address a multitude of highly debilitating chronic diseases, such as IBS and IBD, that remain without optimal therapeutic options,” he added.

Dr. Alesci is a highly regarded healthcare executive with over two decades of experience spanning multiple scientific leadership roles in the government, pharmaceutical and non-profit sectors. He currently serves as Chief Scientist and Strategy Officer for Beyond Celiac – the leading science-driven patient advocacy organization in the U.S. focused on accelerating the development of treatments and a cure for celiac disease, a condition that among others affects his daughter, which has been an important driver of his interest in the GBA. Dr. Alesci was most recently V.P. and Head of R&D Global Patient and Scientific Affairs at Takeda Pharmaceuticals, where he enabled effective partnering between the company and patients organizations throughout the drug life-cycle, ensuring early and continued access to medicines. He has served in several Translational Medicine leadership roles at Wyeth, Pfizer, and Merck, overseeing large and diverse drug portfolios spanning multiple therapeutic areas, including musculoskeletal biology, immunology, and rheumatology. Dr. Alesci received his M.D. (cum laude) and a Ph.D. in Experimental Endocrine and Metabolic Sciences from the University of Messina, School of Medicine (Italy) and completed a Research Fellowship in Rheumatology, Immunology, and Allergy at Georgetown University. After his postgraduate training, Dr. Alesci spent almost a decade conducting cutting-edge basic and translational research on the interplay between the neuroendocrine and immune systems at the National Institutes of Health (NIH). He has published extensively and received multiple recognitions for his research excellence, including two Special Acts of Service Awards by the U.S. Department of Health and Human Services.

About AlphaMeld® AlphaMeld® is an AI-based platform powered by machine learning algorithms. The platform accelerates innovation by identifying alpha signals for targets, drugs, and healthcare products and technologies. Primed with data sets that have been cleaned, curated, and connected for over a decade, the platform generates testable hypotheses based on an ideal mode of pharmacotherapy (antibody, protein replacement, siRNA, mRNA, small molecule, cell and gene therapy, and gene-editing modalities), disease severity, gene ontology, disease pathways, proteinopathies, standard of care, emerging innovation, and enabling technologies while factoring in medical, scientific, strategic, and commercial considerations. AlphaMeld® operates in real-time and in a rapidly changing and diverse data environment.

About InveniAI®InveniAI® LLC, based in Guilford, Conn., is a global leader pioneering the application of artificial intelligence (AI) and machine learning (ML) to transform innovation across drug discovery and development by identifying and accelerating transformative therapies for diseases with unmet medical needs. The company leverages, AlphaMeld®, an AI- and ML-powered platform, to harness petabytes of disparate data sets to recognize and unlock value for drug discovery and development. Numerous industry collaborations in Big Pharma, Specialty Pharma, Biotech, and Consumer Healthcare showcase the value of leveraging our technology to meld human experience and expertise with the power of machines to augment R&D decision-making across all major therapeutic areas. The company leverages AlphaMeld® to augment and accelerate drug discovery programs for our industry partners. For more information, please visit www.inveniai.com.

References:1. Functional gastrointestinal disorders: advances in understanding and managementhttps://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)32115-2/fulltext 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b3baacb2-132d-4ead-b7d0-c935c0ec6745

ContactAnita GanjooInveniAI LLCCorporate CommunicationsT: +1 203 643 8041E-mail: aganjoo@inveniai.com 

  • Check the latest Health news updates and information.
  • Please share this news InveniAI Appoints Industry Leader Dr. Salvatore Alesci as with your friends and family to support us your one share helps us a lot.
Disclaimer: If you need to edit or update this news from compsmag then kindly contact us Learn more

For Latest News Follow us on Google News


Latest Headlines
  • Show all
  • Trending News
  • Popular By week
Microsoft will end support for Windows 10 on October 14, 2025

Microsoft will end support for Windows 10 on October 14, 2025

Microsoft has been dropping lots of hints that it’s ready to launch Windows 11. The software maker is holding a special Windows event to reveal the “next ...
This $2,700 robot dog will carry a single bottle of water for you

Thailand bans meme currencies and NFTs as part of cracking down on encryption

The latest crackdown is part of Thailand’s push for regulatory reform of the crypto market. In May, the Thai Anti-Money Laundering Office (AMLO) announced ...
The Supreme Court will consider LinkedIn’s use of anti-hacking legislation

The Supreme Court will consider LinkedIn’s use of anti-hacking legislation

The justices sent the dispute back to the San Francisco-based 9th U.S. Circuit Court of Appeals to reconsider in light of their June 4 ruling that limited ...
NBA Star James Harden Joins Saks Online  News Board

NBA Star James Harden Joins Saks Online News Board

Saks Chief Executive Officer Marc Metrick told employees in a memo Monday that the retailer is assembling its board to make sure it represents “a variety of ...
CCMF Weekend Leads to a Boom in  News for Some in Myrtle Beach

CCMF Weekend Leads to a Boom in News for Some in Myrtle Beach

“From 7th Avenue to 8th Avenue, completely blocked off,” he said. Becker is the operating partner at ART Burger and Sushi Bar on 8th Avenue. He’s talking about ...
Southgate Mall Corporate Owner File, Chapter 11, says ‘business as usual’ ahead ~ Missoula Current

Southgate Mall Corporate Owner File, Chapter 11, says ‘business as usual’ ahead ~ Missoula Current

Mall officials couldn’t immediately be reached for comment on Monday afternoon. Washington Prime Group completed the purchase of Southgate Mall for $58 ...
The creators of “Regalia: Of Men and Monarchs” are raising funds for their next JRPG

The creators of “Regalia: Of Men and Monarchs” are raising funds for their next JRPG

After their successful crowdfunding of Regalia, the devs return to Kickstarter to fund SacriFire, a JRPG inspired by a wide assortment of the best of the ...
OnePlus Nord CE 5G is optimized for value for money still do you want one?

OnePlus Nord CE 5G is optimized for value for money still do you want one?

Design-wise the two Nords are very similar, though the CE is fractionally thinner and lighter. In fact, it’s the thinnest and lightest OnePlus phone since ...
US SEC Appoints New Director of Corporate Finance and General Counsel

US SEC Appoints New Director of Corporate Finance and General Counsel

She also earned an undergraduate degree from Princeton University and a JD from Harvard University. “Renee brings deep expertise in corporate governance and ...
Sony WF-1000XM4 Vs Apple Airpods Pro

Next Generation of Wireless Earbuds Is Here

Five years on, Apple is still the apex predator with a leading share of the market, but that hasn’t deterred competitors from churning out new wireless ...
Show next
Compsmag - Latest News from tech, business and health
Logo